Affiliations 

  • 1 Universiti Sains Malaysia, School of Medical Sciences, Department of Emergency Medicine, Kubang Kerian, Kelantan, Malaysia
  • 2 Universiti Sains Malaysia, School of Medical Sciences, Department of Emergency Medicine, Kubang Kerian, Kelantan, Malaysia. amararyff@usm.my
  • 3 Universiti Sains Malaysia, School of Medical Sciences, Department of Internal Medicine (Neurology), Kubang Kerian, Kelantan, Malaysia
  • 4 Universiti Sains Malaysia, School of Medical Sciences, Department of Radiology, Kubang Kerian, Kelantan, Malaysia
Med J Malaysia, 2021 Nov;76(6):870-875.
PMID: 34806675

Abstract

INTRODUCTION: Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is effective in treating acute ischaemic stroke. Our primary objective is to assess the outcome of these acute ischaemic stroke (AIS) patients after IV alteplase with the modified Rankin scale (mRS).

METHODS: This is a cross-sectional study in which patients receiving IV alteplase in Hospital Universiti Sains Malaysia, from January 2017 to April 2020 were recruited. Demographical data, National Institutes of Health Stroke Scale (NIHSS) scores, door-to-needle time were recorded. Modified Rankin scale (mRS) scores were evaluated at 90 days after initial therapy. Good and poor functional outcomes were defined as 0-2 and 3-6, respectively.

RESULTS: A total of 30 patients were included in the study with a mean age of 59±11.47 years old. 76.7% of them were male and the rest were female. From the study, onset-toneedle time was 197.47±51.74 minutes, whereas door-toneedle time was 120.93±53.63 minutes. Seventeen (56.3%) patients achieved a favourable score of 0-2 on the mRS at 90 days after treatment. Haemorrhagic transformation occurred in eight (26.7%) of the patients with a mortality rate of 13.3%.

CONCLUSION: 56.7% of our patients showed improvement in the mRS at 90 days post thrombolysis for AIS. Higher baseline NIHSS scores and diabetes mellitus were associated with poorer functional outcomes after thrombolysis.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.